[ORGANIZATION]
AMT-130
Featured in 2 tracked stories · first seen
Situations
uniQure Huntington’s disease gene therapy regulatory filings
3 clusters · 9 sources · last updated
Latest: uniQure releases mixed 48-month clinical data for AMT-130
uniQure has initiated regulatory approval processes for AMT-130, a gene therapy designed to treat the underlying cause of Huntington’s disease. The company submitted a Biologics License Application to the U.S. Food and D